A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome

Alimentary Pharmacology and Therapeutics

Volumn 17, Issue 7, 2003, Pages 895-904

  Kim, H J ^a   Camilleri, M ^a,b   McKinzie, S ^a   Lempke, M B ^a   Burton, D D ^a   Thomforde, G M ^a   Zinsmeister, A R ^a  

^a Clinical Enteric Neuroscience Translational and Epidemiological Research Mayo Clinic   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROBIOTIC AGENT; UNCLASSIFIED DRUG; VSL 3;

ABDOMINAL DISEASE; ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; FEMALE; FLATULENCE; HUMAN; INTESTINE FUNCTION; INTESTINE TRANSIT TIME; IRRITABLE COLON; MALE; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; COLONIC DISEASES, FUNCTIONAL; DIARRHEA; DOUBLE-BLIND METHOD; FEMALE; GASTROINTESTINAL TRANSIT; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PROBIOTICS; TREATMENT OUTCOME;

EID: 0037392231     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2003.01543.x     Document Type: Article

References (37)

1. Rolfe RD. The role of probiotic cultures in the control of gastrointestinal health. J Nutr 2000; 130(2S Suppl.): 396S-402S.
2. Nobaek S, Johansson ML, Molin G, Ahrne S. Jeppsson B. Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol 2000; 95(5): 1231-8.
3. Barone C, Pettinato R, Avola E, et al. Comparison of three probiotics in the treatment of acute diarrhea in mentally retarded children. Minerva Pediatr 2000; 52(3): 161-5.
4. Gomez-Gil B, Roque A, Turnbull JF, Inglis V. A review on the use of microorganisms as probiotics. Rev Latinoam Microbiol 1998; 40(3-4): 166-72.
5. Guandalini S, Pensabene L, Zikri MA, et al. Lactobacillus GG administered in oral rehydration solution to children with acute diarrhea: a multicenter European trial. J Pediatr Gastro enterol Nutr 2000; 30(1): 54-60.
6. Vanderhoof JA, Young RJ. Use of probiotics in childhood gastrointestinal disorders. J Pediatr Gastroenterol Nutr 1998; 27(3): 323-32.
7. Gorbach SL. Probiotics and gastrointestinal health. Am J Gastroenterol 2000; 95(1 Suppl.): S2-4.
8. Saavedra J. Probiotics and infectious diarrhea. Am J Gastroenterol 2000; 95(1 Suppl.): S16-8.
9. Hahn B, Watson M, Yan S, Gunput D, Heuijerjans J. Irritable bowel syndrome symptom patterns: frequency, duration, and severity. Dig Dis Sci 1998; 43(12): 2715-8.
10. Cremonini F. Performance characteristics of scintigraphic gastrointestinal and colonic transit measurements in health: normal values and reliability. Gastroenterology 2002; 122: A1061(Abstract).
11. Talley NJ, Phillips SE, Wiltgen CM, Zinsmeister AR, Melton LJ 3rd. Assessment of functional gastrointestinal disease: the bowel disease questionnaire. Mayo Clin Proc 1990; 65(11): 1456-79.
12. Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol 1997; 32(9): 920-4.
13. Heaton KW, O'Donnell LJ. An office guide to whole-gut transit time. Patients' recollection of their stool form. J Clin Gastroenterol 1994; 19(1): 28-30.
14. Heaton KW, Ghosh S, Braddon FE. How bad are the symptoms and bowel dysfunction of patients with the irritable bowel syndrome? A prospective, controlled study with emphasis on stool form. Gut 1991; 32(1): 73-9.
15. Heaton KW, Radvan J, Cripps H, Mountford RA, Braddon FE, Hughes AO. Defecation frequency and timing, and stool form in the general population: a prospective study. Gut 1992; 33(6): 818-24.
16. Coulie B, Szarka LA, Camilleri M, et al. Recombinant human neurotrophic factors accelerate colonic transit and relieve constipation in humans. Gastroenterology 2000; 119(1); 41-50.
17. Camilleri M, Mayer EA, Drossman DA. et al. Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. Aliment Pharmacol Ther 1999; 13(9): 1149-59.
18. Camilleri M, Northcutt AR, Kong S, Dukes GE, McSorley D, Mangel AW. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet 2000; 355(9209): 1035-40.
19. Camilleri M, Colemont LJ, Phillips SF, et al. Human gastric emptying and colonic filling of solids characterized by a new method. Am J Physiol 1989; 257(2 Part 1): G284-90.
20. Proano M, Camilleri M, Phillips SF, Brown ML, Thomforde GM. Transit of solids through the human colon: regional quantification in the unprepared bowel. Am J Physiol 1990; 258(6 Part 1): G856-62.
21. Camilleri M, Zinsmeister AR, Greydanus MP, Brown ML, Proano M. Towards a less costly but accurate test of gastric emptying and small bowel transit. Dig Dis Sci 1991; 36(5): 609-15.
22. Camilleri M, Zinsmeister AR. Towards a relatively inexpensive, noninvasive, accurate test for colonic motility disorders. Gastroenterology 1992; 103(1): 36-42.
23. Burton DD, Camilleri M, Mullan BP, Forstrom LA, Hung JC. Colonic transit scintigraphy with labeled activated charcoal compared with ion exchange pellets. J Nucl Med 1997; 38(11): 1807-10.
24. Pratt JW. Remarks on zeros and ties in the Wilcoxon signed rank procedures. J Am Statist Assoc 1959; 54(287): 655-67.
25. Hamilton-Miller JMT. Probiotics in the management of irritable bowel syndrome: a review of clinical trials. Microbial Ecol Health Dis 2001; 13: 212-6.
26. Johansson ML, Molin G, Jeppsson B, Nobaek S, Ahrne S, Bengmark S. Administration of different Lactobacillus strains in fermented oatmeal soup: in vivo colonization of human intestinal mucosa and effect on the indigenous flora. Appl Environ Microbiol 1993; 59(1): 15-20.
27. King TS, Elia M, Hunter JO. Abnormal colonic fermentation in irritable bowel syndrome. Lancet 1998; 352(9135): 1187-9.
28. Lembo T, Naliboff B, Munakata J, et al. Symptoms and visceral perception in patients with pain-predominant irritable bowel syndrome. Am J Gastroenterol 1999; 94(5): 1320-6.
29. Serra J, Azpiroz F, Malagelada JR. Impaired transit and tolerance of intestinal gas in the irritable bowel syndrome. Gut 2001; 48(1): 14-9.
30. Stivland T, Camilleri M, Vassallo M, et al. Scintigraphic measurement of regional gut transit in idiopathic constipation. Gastroenterology 1991; 101(1): 107-15.
31. Cann PA, Read NW, Brown C, Hobson N, Holdsworth CD. Irritable bowel syndrome: relationship of disorders in the transit of a single solid meal to symptom patterns. Gut 1983; 24(5): 405-11.
32. Schmulson M, Lee OY, Chang L, Naliboff B, Mayer EA. Symptom differences in moderate to severe IBS patients based on predominant bowel habit. Am J Gastroenterol 1999; 94(10): 2929-35.
33. Prather CM, Camilleri M, Zinsmeister AR, McKinzie S, Thomforde G. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology 2000; 118(3): 463-8.
34. Muller-Lissner SA, Fumagalli I, Bardhan KD, et al. Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther 2001; 15(10): 1655-66.
35. Gionchetti P, Rizzello F, Venturi A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000; 119(2): 305-9.
36. Mimura T, Fernando R, Schreiber S, et al. Once daily high dose probiotic therapy maintains remission and improved quality of life in patients with recurrent or refractory pouchitis: a randomized, placebo-controlled, double-blind trial. Gastroenterology 2002; 122: A81.
37. Lammers K, Vergopoulos A, Babel N, et al. Probiotic therapy as a prophylaxis in ileo-anal anastomosis patients decreases interferon gamma, interleukin 1 beta and interleukin 8 mRNA expression. Gastroenterology 2002; 122: A274.